Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level

scientific article published on 23 May 2020

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41409-020-0952-Z
P932PMC publication ID8376644
P698PubMed publication ID32447349

P50authorNicolaus KrögerQ86950236
P2093author name stringMaximilian Christopeit
Francis Ayuk
Christine Wolschke
Dietlinde Janson
Ute-Marie von Pein
Franziska Modemann
P2860cites workGraft-versus-host disease: why have we not made more progress?Q27012940
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisQ33399980
Managing side effects of JAK inhibitors for myelofibrosis in clinical practiceQ33442340
How I treat refractory acute GVHD.Q35828633
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter surveyQ36862931
Interleukin-2 and regulatory T cells in graft-versus-host diseaseQ37055805
Classification systems for chronic graft-versus-host disease.Q39002161
Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT EffectsQ40936847
Engineered regulatory T cells prevent graft-versus-host disease while sparing the graft-versus-leukemia effect after bone marrow transplantationQ43494585
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.Q49384876
Acute Graft-versus-Host Disease - Biologic Process, Prevention, and TherapyQ49679320
Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.Q54937398
Treatment of Severe Steroid-Refractory Acute-Graft-vs.-Host Disease With Mesenchymal Stem Cells-Single Center ExperienceQ57174876
Favorable impact of extracorporeal photopheresis in acute and chronic graft versus host disease: Prospective single-center studyQ58610776
Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseQ87635679
Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell TransplantationQ88815098
"Do We Know Jack" About JAK? A Closer Look at JAK/STAT Signaling PathwayQ90952392
P921main subjectruxolitinibQ7383611
stem cell transplantationQ65592366
P577publication date2020-05-23
P1433published inBone Marrow TransplantationQ4941523
P1476titleRuxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level

Reverse relations

Q102141667Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host diseasecites workP2860

Search more.